AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05610748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation
Description: In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
Study NCT05121987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
Study NCT05121987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Wound Infusion
Description: Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
Study NCT06186453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Father-Preterm Newborn Bonding Program
Description: B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
Study NCT05127538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gait analysis
Description: Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
Study NCT05127538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Balance Assessment
Description: Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
Study NCT06475573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber probiotic beverages
Description: The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner.
Study NCT06475573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole grain porridge
Description: The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner.
Study NCT05373953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study NCT05373953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: CHF6001 will be administered using the NEXThaler® DPI device
Study NCT06310057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
Study NCT05503654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
Study NCT04716530 — intervention group
Intervention type: OTHER
Intervention: No intervention is associated with the study.
Description: No intervention is associated with the study.
Study NCT06143306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine.
Description: an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
Study NCT06143306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: an ultrasound guided pectoserratus block with 25 mL of saline
Study NCT04854629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinomed active
Description: Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
Study NCT04500756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
Study NCT04500756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
Study NCT01278251 — intervention group
Intervention type: PROCEDURE
Intervention: Distal Biceps Re-Insertion
Study NCT06531161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pill
Description: Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
Study NCT06531161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
Study NCT05777096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised Nordic questionnaires
Description: participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
Study NCT04727879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Synovial membrane biopsy with puncture of synovial fluid
Description: The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
Study NCT04727879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Joint fluid sampling
Description: In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
Study NCT04727879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
Study NCT05815290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
Study NCT05149365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Standard Prophylaxis
Description: Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
Study NCT05149365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prophylaxis
Description: Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
Study NCT05329545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upifitimab rilsodotin
Description: Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
Study NCT05329545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled arm.
Study NCT04771468 — intervention group
Intervention type: DEVICE
Intervention: MOSTCAREup Monitoring
Description: The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
Study NCT04771468 — intervention group
Intervention type: DEVICE
Intervention: Ecocardiography
Description: Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
Study NCT05622851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Contour
Description: Hyaluronic Acid dermal filler
Study NCT05622851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma
Description: Hyaluronic Acid dermal filler
Study NCT06323018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: 4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)
Study NCT06323018 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: 4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
Study NCT04734327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthokine periradicular injection
Description: Ultrasound guided injections
Study NCT04734327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokine epidural injection
Description: Ultrasound guided injections
Study NCT05900960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tea
Description: Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
Study NCT05900960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea
Description: Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
Study NCT05311488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neurofilament light chain
Description: Blood test
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single ascending dose.
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0780
Description: Subjects will receive AZD0780 orally as a single and multiple ascending dose.
Study NCT05311488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In-vivo Meissner Corpuscle imaging
Description: Imaging
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
Study NCT05384262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin orally.
Study NCT05053438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care
Description: Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio.
Study NCT05053438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning
Description: The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
Study NCT04483245 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling
Study NCT05507918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water and clear liquids
Description: Measured oral intake of fluids prior to tonsillectomy
Study NCT04291599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
Study NCT04291599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
Study NCT05123963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
Study NCT05123963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
Study NCT04787250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: Phage will be administered based on patient's matching results.
Study NCT04787250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Stage Exchange Arthroplasty
Description: Performed per the study center's standard of care. No investigational products are used.
Study NCT05612763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self fitting hearing device
Description: comparison of outcomes when device is fit by clinician or self fit
Study NCT05576818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
Description: Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
Study NCT05000502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Description: A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
Study NCT05000502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise intervention
Description: A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
Study NCT05939466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedrocan®-type cannabis (22% THC, <1% CBD)
Description: Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
Study NCT05105308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Assisted Diet (FAD)
Description: A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
Study NCT05105308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeling and Body Investigator_ARFID Division (FBI-ARFID)
Description: A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
Study NCT04563338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
Study NCT04563338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
Study NCT05844787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT101-5
Description: Tablet
Study NCT05311488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction study
Description: Nerve conduction study
Study NCT06079684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent vacuum therapy
Description: Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days.
Study NCT06079684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent vacuum therapy
Description: Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days.